As of 2025-07-05, the Intrinsic Value of Procter & Gamble Health Ltd (PGHL.NS) is 4,597.37 INR. This PGHL.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 5,766.50 INR, the upside of Procter & Gamble Health Ltd is -20.30%.
The range of the Intrinsic Value is 4,076.74 - 5,315.64 INR
Based on its market price of 5,766.50 INR and our intrinsic valuation, Procter & Gamble Health Ltd (PGHL.NS) is overvalued by 20.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 4,076.74 - 5,315.64 | 4,597.37 | -20.3% |
| DCF (Growth 10y) | 4,945.98 - 6,266.33 | 5,507.29 | -4.5% |
| DCF (EBITDA 5y) | 13,334.71 - 15,000.02 | 13,994.00 | 142.7% |
| DCF (EBITDA 10y) | 11,308.28 - 13,581.58 | 12,276.26 | 112.9% |
| Fair Value | 756.60 - 756.60 | 756.60 | -86.88% |
| P/E | 4,445.76 - 13,194.31 | 8,500.52 | 47.4% |
| EV/EBITDA | 5,717.79 - 11,788.72 | 7,732.30 | 34.1% |
| EPV | (407.03) - (488.01) | (447.52) | -107.8% |
| DDM - Stable | 703.40 - 1,253.38 | 978.39 | -83.0% |
| DDM - Multi | 5,196.64 - 6,360.42 | 5,689.84 | -1.3% |
| Market Cap (mil) | 95,723.90 |
| Beta | 0.65 |
| Outstanding shares (mil) | 16.60 |
| Enterprise Value (mil) | 93,979.30 |
| Market risk premium | 8.31% |
| Cost of Equity | 14.96% |
| Cost of Debt | 5.00% |
| WACC | 14.95% |